Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush
June 1, 2026 2:09 PM EDTWedbush analyst Laura Chico raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $46.00) while maintaining a Outperform rating.
The analyst comments "Remain Outperform rated on EWTX, new $52 target. EWTX reached a deal with Servier (not covered) to acquire all... More
